New model continues Mitsubishi's long history with battery electric vehiclesStoried Eclipse name reaches back to its North American debut in 1990New BEV will be...
GRÄFELFING, Germany, June 9, 2026 /PRNewswire/ -- VERTANICAL today announced that Exilby® (VER-01) has received marketing authorization in Germany for the treatment of chronic...
In the news release, AMPERA Establishes Australian Subsidiary to Secure Thorium Supply and Support U.S. Advanced Nuclear Fuel Production, issued 08-Jun-2026 by AMPERA over...
PALM BEACH GARDENS, Fla., June 9, 2026 /PRNewswire/ -- AMPERA today announced its factory-built, scalable, supercritical nuclear energy system will be fueled by thorium...
Company appoints COO and new executive team, opens Texas office, expands into UKI, and earns top national reseller rankings. Recognized with three Global InfoSec Awards.NEW...
EDMONTON, Alberta, June 08, 2026 (GLOBE NEWSWIRE) -- Melcor Developments Ltd. (TSX:MRD), an Alberta-based real estate development and asset management company, announced today that the Toronto Stock Exchange has accepted its notice of intention to make a normal course issuer bid through the facilities of the TSX and on alternative trading systems including: Alpha ATS, Omega ATS, Pure Trading, CHI-X Canada, CX2 and MATCH Now (Triact Canada).
BEIJING, June 8, 2026 /PRNewswire/ -- Posidonia China Night, held in Athens during the Posidonia 2026, one of the world's leading maritime exhibitions, brought...
BEIJING, June 7, 2026 /PRNewswire/ -- Posidonia China Night, held in Athens during the Posidonia 2026, one of the world's leading maritime exhibitions, brought...
VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...
Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6
$45 Million Facility Honors Legendary Alumnus and Elevates the Future of Mustang FootballSAN LUIS OBISPO, Calif., June 6, 2026 /PRNewswire/ -- Cal Poly Athletics...